Global Peptide Vaccine Market & Clinical Pipeline Outlook 2020 The outline of human vaccines had an incredible impact on global health system which resulted in intense reduction of mortality and morbidity caused by numerous diseases.
Vaccines have led to some of the greatest public health achievements ever, including the eradication of naturally occurring smallpox from the globe and the near eradication of polio. This prophylaxis had a long journey through various roads and tunnels to become the
humanities’ key achievement. Despite of the fact, that its mechanism of action remained unclear for centuries. New vaccines coined up in nineteenth century and after the expanded
studies of infectious diseases and processed microorganism vaccination has become an intensive subject to be studied. By all the new advances towards the discovery and understanding of various diseases, our species was able to find a way to eradicate them.
In recent years peptides have emerged as the considerable vaccine candidate owning to their
simple and cost efficient production & development process. Peptides are recognized for being highly selective and efficacious and, at the same time, relatively safe and well
tolerated. Given their attractive pharmacological profile and intrinsic properties, peptides
represent an excellent starting point for the design of novel therapeutics. Several peptide vaccines are now being designed and are encountering phase I and phase II clinical trials.
Peptide vaccines include one or more short or long amino acids sequences, as an antigen combined with a vaccine adjuvant. Thus they fall in the broad category of defined antigen
vaccines, along with the vaccines using proteins, protein sub units, DNA and RNA. They
remain the most immunogenic approaches based on the measures of T-cell responses. Peptide immunogenicity is influenced by the way in which peptides are presented to the immune
system, underscoring the need for multifunctional delivery systems that couple antigen and adjuvant into a single construct.
Cancer immunotherapy by peptide vaccines is one of most emerging and significant segment
that could help pharmaceutical companies to generate more revenues and help patients to alleviate their medical condition. Peptide vaccine for treatment of metastatic prostate
cancer has been introduced in global market. This segment has tendency towards clinical trials as compared to marketed products. Most of the novel products are at different stages of clinical trials which would be introduced in global market in coming years.
For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990
Page 1
Global Peptide Vaccine Market & Clinical Pipeline Outlook 2020 Biomarkers like Melanoma-Associated Antigen 1 (MAGE-1) for melanoma cancer vaccine and NY-ESO-1 for lung cancer are being developed. Their development requires state-of-art
technology due to which they are still not available in market. But confidently these drugs are going to overcome the all hurdles and will become the best suitable candidates in drug market.
A persistent theme in recent peptide based therapeutics is to trigger adaptive antigen specific responses. The next generation drugs will be designed to deliver defined antigenic
peptides, target DCs and PRR agonists. Combinations of carrier with TLR agonists provide new advantages of their cytokine production in enhancing immune response.This is already evident
that in ongoing clinical trials that the benefits of using such vaccines will be large however
safety concerns with diseases like cancer and HIV are still under critical observations. With the growing knowledge of immunological mechanism of adjuvant action, including identifying
the role of specific signaling pathways peptide based vaccines are going to become more attractive and more effective segment of therapeutics.
Although, the opinions of experts in this field are mixed, it is likely that with new product approvals and advanced research, the field of active peptide immunotherapy is self-assured
for dramatic growth in the coming years. Using the gained knowledge and history of passive
immunotherapy development as guiding tool, the peptides will revolutionize the market with modern treatment of varied diseases by the means of peptides vaccines.
“Global Peptide Vaccine Market & Clinical Pipeline Outlook 2020” Report Highlights: • • • • • • • •
Introduction & Classification of Peptide Vaccines
Designing & Production of Peptide Vaccine
Mechanism of Peptide Vaccine
Cancer Immunotherapy with Peptide Vaccine
Global Peptide Vaccine Clinical Pipeline by Company, Indication & Phase
Global Peptide Vaccine Clinical Pipeline: 97 Vaccine
Majority vaccines in Preclinical Phase: 28 Vaccines
Global Peptide Vaccine Market Future Prospects
For Report Sample Contact: neeraj@kuickresearch.com
For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990
Page 2
Global Peptide Vaccine Market & Clinical Pipeline Outlook 2020
Table of Contents 1. Peptide Vaccine: A Prologue to Sub-Unit Vaccines 1.1 Introduction 1.2 Glimpse of Antiquity 2. Need of Peptide Vaccines 2.1 Why Peptides – More Desirable 2.2 Peptide Vaccines V/S Traditional Vaccines 3. Classification of Peptide Vaccines 3.1 On the Basis of Sources Obtained 3.2 On the Basis of Length 3.3 On the Basis of Epitopes 4. Designing & Production of Peptide Vaccine 4.1 Synthetic Peptide Vaccine 4.2 Selection of Peptide Antigen 4.3 Construction of Peptide Antigen 4.4 Chemical Synthesis of Peptide Vaccine 4.4.1 Solution Phase Synthesis (SPS) 4.4.2 Solid Phase Peptide Synthesis (SPPS) 5. Mechanism of Peptide Vaccine 5.1 Induction of Immune Response 5.1.1 Factors Affecting T-Cell Stimulation 5.1.2 Factors Affecting B-cell Stimulation 5.1.3 Factors Affecting T-helper Cells For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990
Page 3
Global Peptide Vaccine Market & Clinical Pipeline Outlook 2020 5.2 Delivery System for Peptide Vaccines 5.2.1 Immunostimulatory Adjuvants 5.2.2 Vaccine Delivery System 5.3 Multiple Antigen Peptide System (MAP) 5.3.1 Use of MAP for Foot-and-Mouth Disease 6. Cancer Immunotherapy with Peptide Vaccine 6.1 Peptides as Tumor Antigens 6.2 Immunotherapy with Peptide Vaccination 6.3 Therapeutic Evaluation of Peptide Vaccine 6.3.1 Prostate Cancer 6.3.2 Breast Cancer 6.3.3 Gastric Cancer 6.3.4 Lung Cancer 6.3.5 Pancreatic Cancer 7. Global Peptide Vaccine Market Overview 7.1 Peptide Vaccine – Does have Long & Secure Future? 7.2 Peptide Patents Insights 7.3 Peptide Vaccine Pipeline Overview 8. Global Peptide Vaccine Market Dynamics 8.1 Accelerative Parameters 8.1.1 Peptidomics 8.1.2 Advances in Vaccine Research 8.1.3 Stronger Clinical Pipeline 8.1.4 Emergence of Biologics in Cancer Therapy For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990
Page 4
Global Peptide Vaccine Market & Clinical Pipeline Outlook 2020 8.2 Commercialization Challenges & Modifications 8.2.1 Funding & Legal Issues 8.2.2 Designing & Manufacturing Challenges 8.2.3 Route of Administration 8.2.4 Peptide Pharmacodynamics & Pharmacokinetics 9. Global Peptide Vaccine Market Future Perspectives 10. Global Peptide Vaccine Clinical Pipeline by Company, Indication & Phase 10.1 Research 10.2 Preclinical 10.3 Phase-I 10.4 Phase-I/II 10.5 Phase-II 10.6 Phase-III 11. Discontinued & Suspended Peptide Vaccine Clinical Pipeline by Company, Indication & Phase 11.1 No Development Reported 11.2 Discontinued 11.3 Market Withdrawal 11.4 Suspended 12. Competitive Landscape 12.1 AFFiRiS 12.2 AlerGenetica 12.3 Anergis 12.4 Antigen Express 12.5 Apitope Technology For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990
Page 5
Global Peptide Vaccine Market & Clinical Pipeline Outlook 2020 12.6 Araclon Biotech 12.7 Artificial Cell Technologies 12.8 Benovus Bio 12.9 Bionor Pharma 12.10 Circassia 12.11 Celgene Corporation 12.12 Galena Biopharma 12.13 Immatics biotechnologies 12.14 Immune Design 12.15 ImmunoCellular Therapeutics 12.16 Invectys 12.17 ISA Pharmaceuticals 12.18 Lytix Biopharma 12.19 Medinet 12.20 Spotlight Innovation (Memcine Pharmaceuticals) 12.21 Merck Serono 12.22 OncoTherapy Science 12.23 Peptech 12.24 Peptinov 12.25 PeptiVir 12.26 Pharmasyntez 12.27 Renaptys Vaccines 12.28 Sumitomo Dainippon Pharma 12.29 TapImmune For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990
Page 6
Global Peptide Vaccine Market & Clinical Pipeline Outlook 2020 12.30 Targovax 12.31 Vaxon Biotech
List of Figures Figure 1-1: History of Vaccines Figure 2-1: Peptides - Amino Acid & Proteins Figure 2-2: Diversification of Vaccines Figure 2-3: Sub-Unit Vaccines V/S Traditional Vaccines Figure 3-1: Classification of Peptide Vaccine by Source Figure 3-2: Classification on Basis of Length Figure 3-3: On the Basis of Epitopes Figure 4-1: Synthetic Peptide Manufacturing Process Figure 4-2: Selection of Synthetic Immunogenic Constructs Figure 4-3: Solid phase Peptide Synthesis v/s Solution Phase Technique. Figure 4-4: Fmoc Cleavage Figure 4-5: Boc Cleavage Figure 5-1: Mechanism of Immune Activation of CD4+ and CD8+ T-Cells Figure 5-2: Delivery System Pathways by Adjuvants Figure 5-3: Liposome & the Modes of Chemically Different Antigen Incorporation. Figure 6-1: TAAs on the Basis of Tissue Distribution Figure 6-2: Vaccination via Peptide Loaded Dendritic Cells Figure 6-3: Mechanism of Action of Sipuleucel-T For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990
Page 7
Global Peptide Vaccine Market & Clinical Pipeline Outlook 2020 Figure 6-4: Use of HER-Vaxx Antigen for Production of Antibodies Figure 6-5: Peptides Applied in Treating Cancer Figure 7-1: Global Peptide Drug Market (US$ Billion), 2014-2020 Figure 7-2: Approved Peptide Drugs Figure 7-3: Global - Peptide Vaccine Clinical Pipeline by Phase (%), 2016 Figure 7-4: Global - Peptide Vaccine Clinical Pipeline by Phase (Numbers), 2016 Figure 7-5: Global - Active & Suspended Peptide Vaccine Clinical Pipeline by Phase (%), 2016 Figure 7-6: Global - Active & Suspended Peptide Vaccine Clinical Pipeline by Phase (Numbers), 2016 Figure 8-1: Global - Peptide Market Favorable Parameters Figure 8-2: Global - Peptide Vaccine Market Commercialization Challenges Figure 8-3: Routes of Administration Figure 12-1: Anergis – Clinical Pipeline Figure 12-2: Apitope Technology – Clinical Pipeline Figure 12-3: Benovus Bio – Clinical Pipeline Figure 12-4: Bionor Pharma – Clinical Pipeline Figure 12-5: Circassia – Clinical Pipeline Figure 12-6: Celgene - Clinical Pipeline Figure 12-7: Galena Biopharma - Clinical Pipeline Figure 12-8: Immatics Biotechnologies - Clinical Pipeline Figure 12-9: Immune Design – Clinical Pipeline Figure 12-10: ImmunoCellular Therapeutics - Clinical Pipeline Figure 12-11: Invectys – Clinical Pipeline Figure 12-12: ISA Pharmaceuticals – Clinical Pipeline For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990
Page 8
Global Peptide Vaccine Market & Clinical Pipeline Outlook 2020 Figure 12-13: Lytix Biopharma - Clinical Pipeline Figure 12-14: Merck Serono – Clinical Pipeline Figure 12-15: Onco Therapy Science – Clinical Pipeline Figure 12-16: Peptinov - Clinical Pipeline Figure 12-17: Sumitomo Dainippon Pharma – Clinical Pipeline Figure 12-18: Tapimmune – Clinical Pipeline Figure 12-19: Targovax - Clinical Pipeline Figure 12-20: Vaxon Biotech - Clinical Pipeline
For Report Sample Contact: neeraj@kuickresearch.com
For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990
Page 9